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Electronic Alert System for Improving Stroke Prevention Among
Hospitalized Oral-Anticoagulation-Na€ıve Patients With Atrial
Fibrillation: A Randomized Trial
G€unther Silbernagel, MD; David Spirk, MD; Adrian Hager, MA; Iris Baumgartner, MD; Nils Kucher, MD
Background-—Many patients with atrial ﬁbrillation (AF) do not receive oral anticoagulants (OAC) for the prevention of stroke and
systemic embolism. We aimed to improve the prescription of (OAC) among hospitalized patients with AF.
Methods and Results-—We developed a computer-based electronic alert system for identifying hospitalized OAC-na€ıve patients
with AF. The alert system contained a CHA2DS2-VASc score calculation tool and provided recommendations for OAC
prescription. The alert system was tested in a 1:1 randomized controlled trial at the University Hospital Bern: Patients with
suspected AF without an active prescription order were allocated to an alert group in which an alert was issued in the electronic
patient chart and order entry system or to a control group in which no alert was issued. The primary end point was the rate of
adequate OAC prescription at hospital discharge, deﬁned as prescription in OAC-na€ıve men and women with CHA2DS2-VASc
score ≥1 and ≥2, respectively. Overall, 889 OAC-na€ıve patients (455 from the alert group and 434 from the control group) were
eligible for analysis. Although the CHA2DS2-VASc score module was used in only 48 (10.5%) patients from the alert group, 100
(22.0%) patients from the alert group versus 69 (15.9%) from the control group received adequate OAC prescription (relative risk
1.38; P=0.021). OAC or antiplatelet therapy was prescribed in 325 (71.4%) patients from the alert group versus 271 (62.4%)
from the control group (P=0.004).
Conclusions-—Versus standard care, the alert system modestly improved OAC prescription among consecutive hospitalized AF
patients.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT02455102. ( J Am Heart Assoc. 2016;5:
e003776 doi: 10.1161/JAHA.116.003776)
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A trial ﬁbrillation (AF) is the most common heart rhythmdisorder and its prevalence is consistently increasing.1,2
One quarter of all 40-year-olds will develop this arrhythmia
during the course of their lives.3 AF increases the risk of
stroke by 5 times4 and doubles the risk of cardiovascular
deaths and strokes after just 1 year.5
Oral anticoagulation therapy (OAC) with vitamin K antago-
nists reduces the risk of stroke and systemic embolismby80%
compared with placebo.6 The direct oral anticoagulants are at
least as effective as vitamin K antagonists. However, direct oral
anticoagulants confer improved safety as compared with
vitamin K antagonists in terms of bleeding complications.7–10
Current guidelines of the American Heart Association, the
American College of Cardiology, and the European Society of
Cardiology recommend the calculation of the CHA2DS2-VASc
score in all patients with AF.6,11 In patients with a score of ≥1
point with the exception of women without additional risk
factor, OAC is recommended for the prevention of stroke and
systemic embolism.11 However, many patients with AF do not
take OAC as recommended by the guidelines.12
Undertreatment can be reduced by increasing adherence
rates to medications at the patient level.13 However, better
quality of treatment may also be achieved by making the
physicians in charge aware of a problem that needs to be
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addressed. In this respect, computer-based electronic alert
systems or clinical decision support systems may improve the
prescription of recommended therapy among hospitalized
patients.14,15
In a randomized controlled clinical trial, a single computer
alert to the physician in charge increased the rate of adequate
prescriptions of thromboprophylaxis and reduced the rate of
venous thromboembolism by 41%.16 It remains unclear
whether computer-based electronic alert systems improve
adequate OAC prescription among hospitalized AF patients.
Methods
Alert System
We developed a computer-based electronic alert system for
identifying consecutive hospitalized OAC-na€ıve patients with
AF and tested the hypothesis that such an alert system would
improve OAC prescription.
The alert system automatically identiﬁed hospitalized
patients with AF without an active OAC prescription in the
electronic order entry system. The alert system was incorpo-
rated into the electronic medical chart and order entry system
of the University Hospital in Bern, Switzerland. It recognized
AF by permanently searching diagnosis lists and physician
notes of the entire electronic patient chart database for free
text entries of AF or its various abbreviations. Alerts were
issued 24 hours after the onset of hospital stay if the
following 4 criteria for an individual patient were present: (1)
AF detected by search criteria; (2) no active prescription order
for anticoagulants, including unfractionated or low-molecular-
weight heparin, fondaparinux, direct oral anticoagulants, or
vitamin K antagonists; (3) at least 1 electronic drug
prescription order other than an anticoagulant had to be in
place in the order entry system; and (4) the patient was
randomized to the alert group. Once the criteria were fulﬁlled,
the alert was issued in the electronic patient chart. The alert
was visible to physicians and nurses, but only physicians were
enabled to respond to the alert. In the ﬁrst alert screen
(Figure 1), the physician was notiﬁed that this patient had
suspected AF without an active OAC prescription. In addition,
the physician was asked to conﬁrm the presence of AF. The
physician in charge had the option to complete the CHA2DS2-
VASc score electronically or to reject the alert if there was no
AF. If AF was present but the physician was unable to
complete the CHA2DS2-VASc score, he or she was able to
postpone the action 3 times. During this time, the alert
remained active. After 3 times of rejecting the alert, the
physician in charge was informed that the alert would
permanently disappear from the electronic patient chart. If
the physician in charge agreed to calculate the CHA2DS2-
VASc score, a new screen with the CHA2DS2-VASc score
items opened (Figure S1). The system automatically entered
the information for the score items sex and age. The system
also calculated the score once the remaining items of the
score were entered. In men with a calculated score <1 and
women with a score <2, no further information was provided
to the physician and the alert disappeared. For all other
patients with increased CHA2DS2-VASc score, an additional
screen opened, containing the current recommendations from
the European Society of Cardiology for stroke prevention in
patients with AF with the following text.11
The alert system was tested and adjusted in a passive run-
in phase in collaboration with the IT Department of the
University Hospital (Inselspital) Bern. Instructions for use of
the alert system were provided in the electronic medical chart
Figure 1. Electronic alert screen that is sent to physicians in charge of patients with atrial ﬁbrillation but
without oral anticoagulation treatment.
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and order entry system. In addition, the heads of the medical
departments were asked to inform their medical staff about
the study.
Study Design
From September 2014 until October 2015 at the University
Hospital Bern, we randomly assigned 1707 patients in a 1:1
fashion to the alert group (n=877) and to the control group
(n=830) where no alert was issued. Randomization was
performed electronically by automatically generating a num-
ber between 1 and 65 535 for each eligible patient. Patients
with odd numbers were randomized to the alert group,
whereas patients with even numbers were randomized to the
control group.
All hospitalized patients aged ≥18 years with AF but
without an active OAC prescription in the order entry system
were included. There were no exclusion criteria.
The study (ClinicalTrials.gov. Identiﬁer: NCT02455102) was
approved by the institutional review board at the University of
Bern. Informed consent by the patients was waived for the
following reasons: (1) The study did not involve an interven-
tion to patients but to physicians. The intervention served to
remind the responsible physician to assess the stroke risk in
patients with AF and to consider the prescription of preventive
measures if an increased risk of stroke was present.
Therefore, the alert was regarded as a clinical decision
support system to help the physician to comply with current
international consensus guidelines. However, the responsible
physician solely carried the responsibility for ordering or not
ordering measures to prevent stroke in patients with AF; (2)
there was no direct or indirect patient contact during the
study (chart review from the hospital stay only; and (3) a
consent procedure in control group patients without alert was
regarded as unethical and would have confounded the
outcome.
As this was a hospital-wide quality improvement initiative,
which involved all departments except pediatrics, approval
was also obtained from the hospital management.
End Points
The primary end point of the study was the rate of adequate
OAC prescription at hospital discharge, deﬁned as prescrip-
tion of any of the recommended drug regimens in OAC-na€ıve
men with CHA2DS2-VASc score ≥1 and in OAC-na€ıve women
with CHA2DS2-VASc score ≥2. Patients were considered OAC-
na€ıve if they were not receiving OAC within 30 days prior to
randomization. The secondary end point was the use of the
CHA2DS2-VASc score calculation tool by the physician in
charge. We also collected data to calculate the HASBLED
score. This score indicates bleeding risk and includes the risk
factors hypertension, abnormal renal or liver function, stroke,
bleeding history or predisposition, labile INR, elderly, and
drugs or alcohol abuse.17
Statistical Analysis
For sample size calculation, we assumed a 30% rate of
adequate OAC prescription in the alert group and a 20% rate
in the control group. Using a power of 90% and a 2-sided
alpha of 5%, at least 412 OAC-na€ıve AF patients per group
were required to reject the null hypothesis. During the
recruitment phase, we continuously monitored all randomized
patients whether they were OAC na€ıve and had conﬁrmed AF
by medical record review. We planned to terminate the patient
recruitment phase once at least 412 OAC-na€ıve AF patients
per group were eligible for analysis.
Data for baseline characteristics and the primary and
secondary end points are presented as absolute numbers and
percentages or as means and standard deviations for
categorical or continuous variables, respectively. P-values
for differences between the groups with regard to end points
are calculated with v2 tests. All P-values are 2-sided and P-
values <0.05 were considered signiﬁcant. For the primary end
point, we additionally calculated the relative risk for ordering
adequate OAC prescription comparing the alert and control
groups. All analyses were performed with IBM SPSS Statistics
for Windows, Version 21.0 (IBM Corp, Armonk, NY).
Results
Patient Characteristics
A total of 889 OAC-na€ıve AF patients were eligible for analysis
(Figure 2). Mean (SD) age was 73.9 (11.3) years. Overall, 359
(40.3%), 48 (5.4%), and 31 (3.5%) patients had paroxysmal,
permanent, and persistent AF, respectively, whereas in 451
(50.7%) patients, the type of AF was unknown. Both groups
were balanced with respect to baseline characteristics with
the exception of a higher rate of systemic hypertension, a
trend toward a higher rate of transient ischemic attack, and a
trend toward a lower rate of renal dysfunction in the alert
group (Table 1). The most frequent reasons for hospital
admission were acute coronary syndrome or other cardiovas-
cular disease (30.0%), cancer (10.6%), nonpulmonary infection
(7.9%), stroke (6.9%), and heart failure (6.4%) (Table 2). The
mean duration of the hospital stay was 9.4 (10.8) days.
Very few patients had a CHA2DS2-VASC score of 0, and
there were only 10 women with a CHA2DS2-VASC score of 1
(Table S1). Overall, 856 (96.3%) of the patients were OAC
candidates based on the CHA2DS2-VASC score. There was no
difference in the proportion of OAC candidates based on the
CHA2DS2-VASC score between the alert (443; 97.4%) and the
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control (413; 95.2%) groups (P=0.083). On the other hand,
391 (44.0%) patients had a HASBLED score of ≥3. There was
no difference in the proportion of patients with HASBLED
score of ≥3 between the alert (208; 45.7%) and the control
(183; 42.2%) groups (P=0.287). There were only 32 (3.6%)
patients with a HASBLED score ≥5 (Table S2). There was no
difference in the proportion of patients with HASBLED score
of ≥5 between the alert (16; 3.5%) and the control (16; 3.7%)
groups (P=0.892).
End Points
Overall, 100 (22.0%) patients from the alert group versus 69
(15.9%) from the control group received an adequate OAC
prescription (Table 3) (relative risk 1.38; P=0.021). In patients
who did not receive an adequate OAC prescription at
discharge, aspirin 100 mg per day was ordered in 199
(56.1%) patients from the alert group and 183 (50.3%)
patients from the control group (P=0.12); an adenosine
diphosphate-receptor antagonist was ordered in 81 (22.8%)
versus 81 (22.3%), respectively (P=0.86); dual antiplatelet
therapy was ordered in 55 (15.5%) and 63 (17.3%), respec-
tively (P=0.51). OAC or antiplatelet therapy was prescribed in
325 (71.4%) patients from the alert group versus 271 (62.4%)
from the control group (P=0.004).
In 48 (10.5%) patients from the alert group, physicians
used the electronic entry system to calculate the CHA2DS2-
VASc score. Among these, 19 (39.6%) calculations were
identical as compared with data obtained from discharge
letters and 16 (37.5%) calculations differed by 1 point. Only 1
patient judged to have an increased score according to
information from the discharge letter was classiﬁed as a low-
risk patient by the physician in charge. In patients from the
alert group, an OAC prescription was present in 11 (22.9%)
patients whose physicians used the CHA2DS2-VASc score
calculation tool and 89 (21.9%) patients whose physicians did
not use it (P=0.87).
Discussion
In this randomized controlled clinical trial, the computer-
based alert system increased adequate OAC prescription
rates as compared to standard of care among consecutive
hospitalized OAC-na€ıve patients with AF.
The ﬁnding is in agreement with the results of a previous
study from our group testing the effectiveness of a clinical
decision support system in the prevention of venous
thromboembolism.16 Taken the ﬁndings from these 2
randomized trials together, there is increasing evidence
supporting the implementation of computerized decision
support systems in cardiovascular medicine. Both alert
systems signiﬁcantly increased adequate prescription rates.
In the present study, the observed rates of adequate OAC
prescription of 22.0% in the alert group and 15.9% in the
control group were somewhat lower than expected (30%
versus 20%), respectively.
Figure 2. Flow chart of the patients whose physicians in charge received electronic alerts reminding
them about patients with atrial ﬁbrillation without ongoing oral anticoagulant treatment. AF indicates atrial
ﬁbrillation; OAC, oral anticoagulation therapy.
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Of note, the tool to calculate the CHA2DS2-VASc score was
used in a minority of patients. Nevertheless, a simple
reminder of untreated AF has obviously increased awareness
and improved treatment quality offered by the physicians in
charge.
Due to the poor use of the CHA2DS2-VASc score tool, we
were only able to evaluate the accuracy of the CHA2DS2-VASc
score calculation in about 10% of the patients from the alert
group. As compared with our calculations of the CHA2DS2-
VASc score based on information from discharge letters, the
CHA2DS2-VASc scores calculated with the tool were quite
accurate. Only 1 patient was classiﬁed as low risk by the tool
but as high risk by information from the discharge letter.
Interestingly, the use of the CHA2DS2-VASc score calculation
tool had no impact on the OAC prescription rate. Reasons for
not using the CHA2DS2-VASc score tool may include knowl-
edge of the CHA2DS2-VASc score prior to the alert, time
constraints, the high rate of non-sense alerts, and known
contraindication to OAC because of an increased risk of
bleeding. In this respect it was notable that 40% of the
Table 1. Clinical Baseline Characteristics of the Patients
Stratiﬁed for Randomization Group
Randomization Group
Control Alert
Number 434 455
Sex
Male 292 (67.3) 300 (65.9)
Female 142 (32.7) 155 (34.1)
Age (y) 73.3 (11.8) 74.4 (10.9)
Type of atrial fibrillation
Paroxysmal 174 (40.1) 185 (40.7)
Permanent 25 (5.8) 23 (5.1)
Persistent 15 (3.5) 16 (3.5)
Unknown 220 (50.7) 231 (50.8)
History of stroke 27 (6.2) 41 (9.0)
History of transient ischemic attack 13 (3.0) 26 (5.7)
History of venous thromboembolism 25 (5.8) 35 (7.7)
History of systemic embolism 4 (0.9) 3 (0.7)
Vascular disease* 154 (35.5) 179 (39.3)
Congestive heart failure† 134 (30.9) 137 (30.1)
Diabetes mellitus 93 (21.4) 104 (22.9)
Systemic hypertension 229 (52.8) 276 (60.7)
Bleeding‡ 143 (32.9) 140 (30.8)
Renal dysfunction§ 100 (23.0) 80 (17.6)
Hepatic impairmentk 16 (3.7) 15 (3.3)
Alcohol intake¶ 23 (5.3) 20 (4.4)
Antiplatelet or nonsteroidal
antirheumatic drug
235 (54.1) 265 (58.2)
Values are numbers and percentages for categorical data or means with standard
deviation for continuous data.
*Myocardial infarction, peripheral artery disease, or aortic plaque.
†Chronic heart failure or left ventricular ejection fraction ≤40%.
‡History of major bleeding and predisposition (anemia).
§Creatinine clearance <30 mL/min.
kAminotransferase >39 upper limit of normal.
¶≥Eight units alcohol per week.
Table 2. Diagnoses, Which Were the Main Reason for
Hospital Admission, Stratiﬁed by Randomization Group
Reason
Group
Control Alert
Cardiovascular disease/rhythm disorder 129 (29.7) 138 (30.3)
Heart failure (NYHA III and IV) 31 (7.1) 26 (5.7)
Acute stroke (ischemic or hemorrhagic) 27 (6.2) 35 (7.7)
Cancer 48 (11.1) 46 (10.1)
Nonpulmonary infection or sepsis 35 (8.1) 35 (7.7)
Gastrointestinal bleeding 11 (2.5) 6 (1.3)
Pneumonia 8 (1.8) 6 (1.3)
COPD 3 (0.7) 0 (0.0)
Renal failure* 8 (1.8) 5 (1.1)
Inflammatory or rheumatic disease 4 (0.9) 4 (0.9)
Liver cirrhosis or hepatobiliary disease 2 (0.5) 7 (1.5)
Endocrine disease (including diabetes) 1 (0.2) 3 (0.7)
Hematological disease (nonmalignant) 0 (0.0) 1 (0.2)
Other medical condition 127 (29.3) 143 (31.4)
Values are numbers and percentages. COPD indicates chronic obstructive pulmonary
disease; NYHA, New York Heart Association.
*Creatinine clearance <30 mL/min.
Table 3. Vitamin K Antagonist and Direct Oral Anticoagulant
Therapy Stratiﬁed for Randomization Group
Group
P Value*Control Alert
Any prescription
Vitamin K antagonist 32 (7.4) 52 (11.4) 0.039
Direct oral anticoagulant 38 (8.8) 48 (10.5) 0.366
Total 70 (16.1) 100 (22.0) 0.027
Adequate prescription
Vitamin K antagonist 32 (7.4) 52 (11.4) 0.039
Direct oral anticoagulant 37 (8.5) 48 (10.5) 0.305
Total 69 (15.9) 100 (22.0) 0.021
Values are numbers and percentages.
*Calculated with v2 test.
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patients in the study had a HASBLED score ≥3, indicating
increased bleeding risk.11 This may also be a reason for the
overall low OAC prescription rate in the study. Of relevance, a
considerable amount of patients received antiplatelet therapy,
and as compared with the control group more patients
from the alert group received OAC or antiplatelet therapy.
A previous clinical decision support system was developed to
facilitate clinical decision making with regard to OAC treat-
ment in AF patients.18 This system included both the
calculation of the CHA2DS2-VASc and the HASBLED scores.
However, it did not include what we think is the main beneﬁt
of our electronic alert system, namely, to issue alerts to
patients with suspected AF without an active OAC prescrip-
tion.
A limitation of our alert system was the high rate of non-
sense alerts for patients who were not OAC-na€ıve because
alerts were often issued before anticoagulation treatment was
ordered through the electronic prescription system. Prior to
the randomization phase, the rate of non-sense alerts was
reduced by issuing alerts not directly on admission but
24 hours after the onset of the hospital stay. Very few
departments at the Inselspital did use the electronic patient
chart only for entering diagnoses but not for prescription of
pharmaceutical treatments. This problem was then solved
through sending alerts only if at least 1 drug has been
prescribed through the alert system at 24 hours. Another
problem was that many patients had paused OAC therapy due
to planned surgical procedures. Patients with paused OAC
therapy were identiﬁed by reviewing medical discharge letters
and then excluded from the analysis. In addition, alerts were
issued for several patients in whom AF was identiﬁed by the
alert system but not conﬁrmed by the treating physician. We
think that the use of the CHA2DS2-VASc score calculation tool
and the rate of adequate OAC prescription can be further
improved by reducing the rate of non-sense alerts. We plan to
continuously improve the identiﬁcation of OAC-na€ıve patients
and integrate the alert system in routine clinical practice.
Further limitations of our study were the single-center setting,
and the lack of systematic evaluation of why anticoagulation
was not given. Physicians’ acceptance of the alert was not
assessed systematically either, nor was the potential impact
of other electronic alert systems on the present alert system
considered. The strengths of the present study include its
randomized design and chart reviews of bleeding and stroke
risks. The intervention was designed to modify physician
behavior, but randomization was at the patient level. Since
individual physicians may have treated several patients, the
observations are not independent, and the outcome analysis
typically should account for clustering of patients within
physicians. However, since more than 500 physicians were
involved in the study, such a cluster analysis was deemed less
helpful.
An increase in the prescription rate of anticoagulant
treatment in AF may translate into a reduction of the future
risk of stroke. We did not collect data to investigate the effect
of the alert system on the risk of stroke and systemic
embolism. A prospective multicenter trial testing the effects
of the alert system on end points is therefore encouraged. The
total cost for the entire project was US $230 000, of which
the majority was used for developing and testing of the alert
system. Therefore, the implementation of the alert system in
other hospitals seems feasible.
In conclusion, we developed and tested a novel electronic
decision support system for improving adequate stroke
prevention measures among hospitalized OAC-na€ıve patients
with AF. In comparison to routine clinical practice, this alert
system modestly increased adequate OAC prescription. Our
results suggest that hospitals with electronic patient chart
and order entry systems may consider implementing similar
computer-based alerts to increase physician awareness of
untreated AF.
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SUPPLEMENTAL MATERIAL 
Table S1. The categories of the CHA2DS2-VASC-Score stratified for randomization group 
 
 
 Group 
 ________________________________________________ 
CHA2DS2VASC-Score Control Alert 
0 15 (3.5) 8 (1.8) 
1 (women) 6 (1.4) 4 (0.9) 
1 (men) 38 (8.8)  39 (8.6)  
2 69 (15.9) 57 (12.5) 
3 89 (20.5) 98 (21.5) 
4 87 (20.0) 97 (21.3) 
5 75 (17.3) 63 (13.8) 
6 30 (6.9) 57 (12.5) 
7 19 (4.4) 24 (5.3) 
8 6 (1.4) 8 (1.8) 
9 0 (0.0) 0 (0.0) 
   
 
Values are numbers and percentages.  
Table S2. The categories of the HASBLED-Score stratified for randomization group 
 
 
 Group 
 ________________________________________________ 
HASBLED-Score Control Alert 
0 32 (7.4) 25 (5.5) 
1 79 (18.2) 84 (18.5) 
2 140 (32.3) 138 (30.3) 
3 112 (25.8) 136 (29.9) 
4 55 (12.7) 56 (12.3) 
5 13 (3.0) 14 (3.1) 
6 3 (0.7) 2 (0.4) 
7 0 (0.0) 0 (0.0) 
8 0 (0.0) 0 (0.0) 
9 0 (0.0) 0 (0.0) 
   
 
Values are numbers and percentages. 
  
Figure S1. CHA2DS2-VASc score calculation tool for physicians in charge of patients with 
atrial fibrillation but without ongoing oral anticoagulant treatment  
 
